Introduction
============

COPD is one of the leading causes of mortality and morbidity around the world, causing a huge and growing economic and social burden.[@b1-copd-14-163]--[@b4-copd-14-163] Chronic inflammation and irreversible airflow obstruction are the main characteristics of COPD, often accompanied by structural changes of the lung.[@b5-copd-14-163] This chronic inflammation response may induce parenchymal tissue destruction and recomposition of extracellular matrix (ECM). In the lung, type I collagen could form a tight fibrillar network throughout the large conducting airways, bronchi, and bronchioles, providing the mechanical strength and stability required for their proper functions.[@b6-copd-14-163],[@b7-copd-14-163] Furthermore, among a variety of proteins participating in the progression of small airway remodeling in COPD, type I collagen was the predominant constituent of the altered ECM composition.[@b8-copd-14-163]

In the process of type I collagen synthesis, type I pro-collagen chains are firstly polymerized to form procollagen trimer from the C-terminus nucleation. Then, after shedding the C-terminus trimeric nucleus which is known as procollagen type I C-terminal peptide (PICP), the trimer is deposited in tissues as the insoluble fibrillary collagen. Additionally, mature type I collagen with type-specific collagen cross-links can liberate from tissues and regain solubility via enzymatic degradation into small fragments, and the C-terminal telopeptide is known as C-terminal telopeptide of type I collagen (ICTP).[@b6-copd-14-163],[@b9-copd-14-163] Therefore, the expression and release of PICP and ICTP could reflect the ongoing turnover of deposition and degradation of type I collagen in tissues.

In a previous study of asthma, airway inflammatory factors could affect the levels of ICTP and PICP in sputum.[@b10-copd-14-163] Moreover, PICP and ICTP, were involved in the airway remodelling caused by the disorder of ECM deposition. Similar to asthma, small airway remodelling is one of the pathological mechanisms of COPD.[@b11-copd-14-163] Taking these facts together, we hypothesized that the imbalanced collagen turnover in COPD lung might be reflected by circulating levels of PICP and ICTP, which could be accompanied by the release of inflammatory factors.

To validate this hypothesis, we performed a multicenter cohort study to investigate whether serum levels of PICP and ICTP were different between patients with stable COPD and healthy subjects and further analyzed the association between these markers and some clinical variables, such as smoke exposure, lung function, and inflammatory markers.

Patients and methods
====================

Study population
----------------

Subjects in this study were recruited from Zhongshan Hospital of Fudan University (a tertiary teaching hospital) and Shanghai Dahua Hospital (a secondary district hospital) from December 2011 to October 2012. Participants without COPD from a general population were recruited into the control group, and stable COPD patients aged 45 years and older were enrolled into the COPD group. Subjects with stable COPD were mainly recruited from respiratory outpatient departments and respiratory wards. The diagnosis of COPD was made according to the GOLD criteria. Briefly, COPD was diagnosed when post-bronchodilator FEV~1~/FVC ratio was \<0.70.[@b4-copd-14-163]

Participants who met any of the following criteria were excluded: 1) patients with congestive heart failure, pneumosilicosis, asthma, bronchiectasis, active pulmonary tuberculosis, interstitial lung disease, obstructive bronchiolitis, pleural effusion, diffuse panbronchiolitis, lung cancer, or a history of pneumonectomy; 2) those having large airway abnormality that caused respiratory symptoms similar to COPD and/or airflow limitation; 3) exacerbation of COPD within 4 weeks; 4) patients with medical records of osteoporosis or bone metastasis of malignant tumors; and 5) those who had been taking oral or intravenous corticosteroid for treating other diseases.

Study procedure and data collection
-----------------------------------

For all participants, baseline characteristics and lung function were recorded. Baseline characteristics included age, gender, weight, height, smoking status (never smoker, ever smoker, or current smoker), pack-years of smoking, and number of acute exacerbations in the previous year. Non-smokers were defined as having \<5 pack-years of cigarettes; otherwise, the subjects were classified as smokers. Spirometric measurements were performed according to international guidelines using a calibrated MS-PFT spirometer (Jaeger Co, Hoechberg, Germany) before and after inhalation of 400 µg salbutamol.[@b12-copd-14-163] Serum samples were collected for subsequent measurement of C-reactive protein (CRP), IL-6, IL-8, tumor necrosis factor-α (TNF-α), PICP, and ICTP.

For patients with COPD, results of extra two questionnaires -- COPD assessment test and modified Medical Research Council scale -- were collected for evaluating health status impairment and dyspnea.[@b13-copd-14-163],[@b14-copd-14-163] The COPD grade based on FEV~1~% was calculated as shown in [Table 1](#t1-copd-14-163){ref-type="table"}. COPD severity group was also assessed according to A, B, C, D classification proposed by GOLD reports.[@b4-copd-14-163]

Quantification of biomarkers in serum samples
---------------------------------------------

Commercial ELISA kits used for measuring serum levels of IL-6 (cat no SEA079Hu), IL-8 (cat no SEA080Hu), TNF-α (cat no SEA133Hu), and PICP (cat no SEA570Hu) were purchased from Uscn Life Science lnc (Wuhan, China). The commercial competitive radioimmunoassay kits were used to measure serum levels of ICTP (cat no 06099; UniQ, Orion Diagnostica, Espoo, Finland). These procedures were performed according to the manufacturer's instructions.

Ethics statement
----------------

This study was approved by the Ethics Committee of Zhongshan Hospital of Fudan University and registered in the Chinese Clinical Trials Registry (ChiCTR-OCC-11001621). This study was conducted in accordance with the Declaration of Helsinki and written informed consent was received from all participants.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 19.0 (SPSS Inc, Chicago, IL, USA). All continuous variables were expressed as mean ± SEM. D'Agostino and Pearson omnibus normality test was performed for continuous variables. For normally distributed data, unpaired *t*-tests or one-way ANOVA followed by Bonferroni post-test was performed to determine whether the differences between the groups were statistically significant. Otherwise, comparisons were made using Mann--Whitney test or Kruskal--Wallis analysis followed by Dunn's multiple comparison test. Correlation analyses were carried out using Pearson or Spearman methods depending on the normality of data distribution. For categorical variables, a chi-squared (*χ*^2^) test and Spearman rank correlation analysis were used to make comparisons between groups. Differences were considered significant at the level of *P*\<0.05.

Results
=======

Baseline characteristics
------------------------

In our study, a total of 20 patients with stable COPD and 25 controls without COPD were recruited, including 13 male, 7 female in the COPD group and 16 male, 9 female in the control group. Demographic data, smoking habit, COPD grade based on post-bronchodilator FEV~1~%, and COPD severity group are described in [Tables 2](#t2-copd-14-163){ref-type="table"} and [3](#t3-copd-14-163){ref-type="table"}. Age and gender had no significant difference between the COPD group and the control group. Subjects with COPD smoked more heavily than controls, but the differences were not statistically significant.

Inflammatory biomarkers
-----------------------

As shown in [Table 4](#t4-copd-14-163){ref-type="table"}, serum levels of CRP, IL-6, IL-8, and TNF-α were all increased in patients with stable COPD compared to control subjects without COPD, but only changes of IL-6 had a statistically significant difference.

PICP and ICTP
-------------

Compared with non-COPD controls, serum PICP was significantly elevated in subjects with COPD (3,178±87.3 pg/mL vs 2,533±190.1 pg/mL, *P*=0.016), and concentration of ICTP was slightly decreased (948±67.2 pg/mL vs 822±80.3 pg/mL, *P*=0.236) ([Figure 1A and C](#f1-copd-14-163){ref-type="fig"}). Subgroup analysis stratified by smoking history was then performed for PICP. In both controls and patients with COPD, no significant difference was observed between smokers and non-smokers, although smokers showed a trend toward a higher level of PICP with insufficient statistical power ([Figure 1B](#f1-copd-14-163){ref-type="fig"}).

Our study suggested that the amount of smoke exposure and the value of lung function seemed to have no correlation with systemic concentrations of PICP ([Table 5](#t5-copd-14-163){ref-type="table"}). We also investigated the associations between systemic inflammatory biomarkers and serum levels of PICP. Serum concentration of PICP was positively correlated with IL-6 and IL-8 concentrations, but no statistically significant association was observed between serum levels of ICTP and IL-6 or IL-8.

Discussion
==========

In the present study, we found that the serum level of PICP was significantly higher in COPD subjects than that in normal subjects, while ICTP was slightly declined with insufficient statistical power. Among the inflammatory mediators that we measured, only the increased IL-6 achieved statistical significance in patients with COPD. Moreover, the expression of PICP was positively correlated with serum IL-6 and IL-8 concentration. However, no correlation was found between the serum levels of ICTP and IL-6 or IL-8 in COPD patients.

Abnormal and excessive deposition of the ECM in small airway walls is a major pathological processes in COPD,[@b7-copd-14-163],[@b15-copd-14-163] in which type I collagen is an important molecule. The amount of insoluble collagen in tissues is mainly regulated by the process of synthesis and degradation,[@b7-copd-14-163] and PICP is a reliable biomarker of synthesis of type I collagen.[@b16-copd-14-163] Thus, the increased concentration of PICP in the serum of COPD patients indicates that PICP might be associated with the occurrence and progression of airway remodeling. Furthermore, we speculate that the serum concentration of PICP may be correlated with the severity of COPD, but further research is needed to confirm this hypothesis. Significant differences between PICP and FEV~1~% were not observed, probably due to the small sample size.

Some previous studies demonstrate that IL-6 is released from fibroblasts, endothelial cells, and epithelial cells in COPD, and could induce collagen synthesis.[@b17-copd-14-163]--[@b19-copd-14-163] Consistent with these studies, we also observed the increased concentration of IL-6 in the COPD group.

In our study, the concentration of PICP in serum was positively correlated with the concentration of IL-6 and IL-8 in the serum. Some studies showed that rhIL-6 could infiltrate in the peritendinous tissue, resulting in a remarkable increase of the peritendinous concentration of PICP.[@b20-copd-14-163] Moreover, animal studies proved that IL-6-knockdown mice had declined concentrations of PICP compared with normal mice.[@b20-copd-14-163] Therefore, the correlation of IL-6 and PICP in COPD patients indicated that IL-6 could promote the deposition of ECM in airways and the development of airway remodeling by cooperating with PICP. IL-8, a chemotactic factor for neutrophils, has been confirmed to be responsible for acute exacerbation and disease progression of COPD.[@b21-copd-14-163] Our previous study demonstrated that IL-6 and IL-8 were mainly produced by pulmonary fibroblasts and could participate in the maintenance of the persistent inflammation in COPD lungs.[@b22-copd-14-163] Taking these findings into account, we postulated that both IL-6 and IL-8 could promote collagen synthesis and ECM deposition in COPD. However, the mechanism of IL-6 and/or IL-8 in stimulating the production of PICP in COPD has not yet been elucidated. The association between ICTP and IL-6 or IL-8 was not found in our study (data not shown). A large sample may be needed to testify our results.

Our study has limitations. Firstly, since the sample size was small, the results may be biased and could not represent the overall COPD populations. Secondly, diseases other than COPD could affect the levels of PICP and ICTP in COPD patients, including osteoporosis, glucocorticoids, and metastatic bone cancer.[@b10-copd-14-163],[@b23-copd-14-163],[@b24-copd-14-163] As the critical factors in bone synthesis and resorption, PICP and ICTP are closely associated with the development of osteoporosis.[@b25-copd-14-163] At the same time, osteoporosis is one of the common comorbidities in COPD patients, with a prevalence rate of 22%--44%. In addition, long-term use of corticosteroids could lead to the fluctuation of the levels of PICP and ICTP.[@b26-copd-14-163] Corticosteroids are widely used in COPD patients to reduce the airway and/or systemic inflammation, with an increased risk for osteoporosis.[@b26-copd-14-163] PICP and ICTP also play significant roles in the diagnosis and prognosis of metastatic bone cancer.[@b27-copd-14-163] To limit these confounding factors, we excluded the subjects with medical records of osteoporosis or bone metastasis of malignant tumors or receiving systemic corticosteroids.

Conclusion
==========

Despite these limitations, we still can draw the conclusion from the current data that the serum PICP could serve as a surrogate marker of the airway remodeling in COPD. Moreover, inflammation represented by IL-6 and IL-8 might play an important role in stimulating collagen synthesis. Therefore, we suggest that the measurements of serum PICP in combination with serum IL-6 and/or IL-8 might potentially be useful for assessing the imbalanced status of ECM in COPD.
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###### 

Definition and severity grading of COPD according to degree of airflow obstruction

  Grade                        Post-bronchodilator spirometry test
  ---------------------------- -------------------------------------------------------------------------------------------
                               
  Grade 1 (mild COPD)          FEV~1~/FVC \<70%; FEV~1~%pred ≥80%
  Grade 2 (moderate COPD)      FEV~1~/FVC \<70%; 50% ≤FEV~1~%pred \<80%
  Grade 3 (severe COPD)        FEV~1~/FVC \<70%; 30% ≤FEV~1~%pred \<50%
  Grade 4 (very severe COPD)   FEV~1~/FVC \<70%; FEV~1~%pred \<30% or FEV~1~%pred \<50% plus chronic respiratory failure

**Abbreviation:** %pred, percentage of predicted.

###### 

Baseline characteristics between control and COPD groups

  Characteristics                        Control       COPD          *P*-value
  -------------------------------------- ------------- ------------- -----------
                                                                     
  N                                      25            20            
  Male/female, n                         16/9          13/7          0.956
  Age (years)                            73.1±2.6      78.3±1.7      0.258
  Smoker/non-smoker, n                   10/15         12/8          0.192
  Pack-years                             10.8±3.2      22.4±5.2      0.098
  FEV~1~, post-bronchodilator, L         1.628±0.123   0.878±0.051   \<0.001
  FEV~1~ %pred, post-bronchodilator, %   74.6±5.0      45.2±2.2      \<0.001
  FEV~1~/FVC%, %                         78.5±1.9      57.1±2.3      \<0.001

**Note:** Data are expressed as mean ± SEM.

**Abbreviation:** %pred, percentage of predicted; SEM, standard error of the mean.

###### 

Combined assessment of severity conditions for patients with COPD

  Combined COPD assessment   GOLD grade   GOLD group
  -------------------------- ------------ ------------
                                          
  Grade 1/group A, n (%)     0 (0)        0 (0)
  Grade 2/group B, n (%)     9 (45)       3 (15)
  Grade 3/group C, n (%)     11 (55)      1 (5)
  Grade 4/group D, n (%)     0 (0)        16 (80)

###### 

Comparison of inflammatory biomarkers between the COPD and control groups

  Inflammatory biomarker   Control    COPD       *P*-value
  ------------------------ ---------- ---------- -----------
                                                 
  CRP (mg/L)               10.3±2.3   17.8±5.5   0.383
  IL-6 (pg/mL)             11.7±4.3   30.5±9.9   0.047
  IL-8 (pg/mL)             35.9±5.7   51.9±7.7   0.178
  TNF-α (pg/mL)            12.8±2.9   10.1±1.7   0.708

**Note:** Data are expressed as mean ± SEM.

**Abbreviations:** CRP, C-reactive protein; TNF, tumor necrosis factor; SEM, standard error of the mean.

###### 

Correlation analysis between serum levels of PICP, clinical variables, and inflammatory biomarkers

  Variables             Serum levels of PICP   
  --------------------- ---------------------- ---------
                                               
  Smoking (pack-year)   0.134                  0.411
  FEV~1~ %pred (%)      −0.250                 0.119
  FEV~1~/FVC% (%)       −0.251                 0.118
  CRP (mg/L)            0.077                  0.646
  IL-6 (pg/mL)          0.483                  \<0.001
  IL-8 (pg/mL)          0.472                  0.001
  TNF-α (pg/mL)         0.220                  0.147

**Abbreviations:** PICP, procollagen type I C-terminal peptide; %pred, percentage of predicted; CRP, C-reactive protein; TNF, tumor necrosis factor.
